Source comparison
CJC-1295 No DAC Help Muscle Growth Research: Comparison of GH-Stimulating Peptides
CJC-1295 no DAC (Modified GRF 1-29) GHRH receptor agonist, amplifies endogenous GH pulses 30 minutes 2–3 times daily at 100–200 mcg Peak at 24–36 hours, returns to baseline 48–72 hours post-dose Muscle protein synthesis studies requiring preserved pulsatile GH
This comparison does not assign a generated winner or score.
- CJC-1295 no DAC (Modified GRF 1-29)
- GHRH receptor agonist, amplifies endogenous GH pulses
- 30 minutes
- 2–3 times daily at 100–200 mcg
- Peak at 24–36 hours, returns to baseline 48–72 hours post-dose
- Muscle protein synthesis studies requiring preserved pulsatile GH dynamics and minimal receptor desensitization
- Best choice for protocols requiring physiological GH patterns; demands strict dosing compliance due to short half-life
- CJC-1295 with DAC
- GHRH receptor agonist with albumin-binding modification
- 6–8 days
- Once weekly at 1000–2000 mcg
- Sustained elevation for 7–14 days per dose
- Long-term growth studies where continuous IGF-1 elevation is desired over pulsatile patterns
- Convenient dosing but risks GH receptor downregulation; less suitable for studies examining acute anabolic responses
- Ipamorelin
- Ghrelin receptor agonist (growth hormone secretagogue)
- 2 hours
- 2–3 times daily at 200–300 mcg
- Moderate IGF-1 increase, peaks 12–24 hours
- Studies requiring GH release without cortisol or prolactin co-secretion
- Synergistic when combined with CJC-1295 no DAC; minimal side effect profile but lower peak GH amplitude
- GHRP-2
- Ghrelin receptor agonist with broader hormone release
- 20 minutes
- 3–4 times daily at 100–200 mcg
- Rapid but transient IGF-1 response within 6–12 hours
- Acute GH response studies; combined protocols for maximal pulse amplitude
- Produces higher GH peaks than Ipamorelin but stimulates cortisol and prolactin; requires more frequent dosing than CJC-1295 no DAC
- MK-677 (Ibutamoren)
- Oral ghrelin receptor agonist
- 24 hours
- Once daily at 10–25 mg
- Sustained IGF-1 elevation for 24+ hours per dose
- Convenience-focused protocols where daily injections are impractical
- Oral bioavailability advantage but causes significant appetite increase and potential insulin resistance with chronic use